Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Candidate Pathways, Whole Genome Scans
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

Cancer Research 68, 1697-1706, March 15, 2008. doi: 10.1158/0008-5472.CAN-07-5492
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Chen, R.-N.
Right arrow Articles by Lin, K.-H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, R.-N.
Right arrow Articles by Lin, K.-H.

Molecular Biology, Pathobiology, and Genetics

Thyroid Hormone Receptors Suppress Pituitary Tumor Transforming Gene 1 Activity in Hepatoma

Ruey-Nan Chen1, Ya-Hui Huang1, Chau-Ting Yeh2,3, Chen-Hsin Liao1 and Kwang-Huei Lin1

Departments of 1 Biochemistry and 2 Medicine, School of Medicine, Chang-Gung University, Taoyuan, Taiwan, and 3 Liver Research Unit, Chang-Gung Medical Center, Taipei, Taiwan, Republic of China

Requests for reprints: Kwang-Huei Lin, Department of Biochemistry, Chang-Gung University, 259 Wen-hwa 1 Road, Taoyuan, Taiwan, Republic of China. Phone/Fax: 886-3-2118263; E-mail: khlin{at}mail.cgu.edu.tw.

Key Words: PTTG1 • thyroid hormone • receptor

Pituitary tumor transforming gene 1 (PTTG1) is expressed in most tumors. However, whether thyroid hormone (T3) and its receptors (TR) regulate PTTG1 in human hepatocellular carcinomas (HCC) remains unclear. Previous cDNA microarrays revealed PTTG1 is down-regulated by T3/TR. This study investigated the significance of PTTG1 regulation by T3 in HCC cells. The PTTG1 mRNA and protein expression were repressed by T3 in HCC cell lines overexpressing TR. However, after knockdown of TRs expression by RNA interference, PTTG1 repression by T3 was abolished. Similar results were observed in thyroidectomized rats. To localize the regulatory region in the PTTG1 promoter, serial deletions within the PTTG1 promoter region were constructed. The promoter activity of the PTTG1 gene was repressed (25–51%) by T3. Additionally, these findings indicate that PTTG1 may be regulated by Sp1. The critical role of the –594 and –520 Sp1 binding sites was confirmed by electrophoretic mobility shift assay. Transfection with Sp1 expression vector enhanced the activity of the PTTG1 promoter fragment reporter. Also, Sp1 was down-regulated in HCC cells and in thyroidectomized rat after T3 treatment. Additionally, ectopic expression of PTTG1 promotes cell proliferation in Hep3B hepatoma cells. Conversely, knockdown of PTTG1 or Sp1 expression reduced cell proliferation in HepG2 cells. Notably, the expression of PTTG1 and Sp1 was inversely correlated with the expression of TR proteins in HCC. Together, these findings indicate that PTTG1 gene expression is mediated by Sp1 and is indirectly down-regulated by T3. Finally, overexpression of PTTG1 or SP1 in HCCs is TR-dependent and crucial in the development of HCC. [Cancer Res 2008;68(6):1697–1706]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 2008 by the American Association for Cancer Research.